Eli Lilly and Co at Guggenheim Partners Healthcare Talks Oncology Days (Virtual) Transcript
Okay. Great. Thanks, everybody, for joining us. Good afternoon, and welcome to Guggenheim's Fourth Annual Oncology Conference and today's fireside chat discussion with Eli Lilly. I'm Seamus Fernandez, Guggenheim's global biopharma analyst.
I'm joined by Jake Van Naarden, President of Lilly Oncology; and Dr. David Hyman, Chief Medical Officer of Lilly Oncology.
Jake, David, thanks so much for joining us here today.
Questions & Answers
So I'm going to jump right in with a question for Jake. Jake, coming from what we all assume is a very fast-moving biotech in Loxo Oncology, you've been on the Lilly platform for several years now. I think many people have this feeling that pharma is a slow-moving kind of plotting organizations that just have a lot of capital to deploy. What's been your experience at
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |